Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Cardiovascular Imaging Reports
Published in: Current Cardiovascular Imaging Reports 4/2015

01-04-2015 | Molecular Imaging (R Russell, Section Editor)

Application of Cardiac Neurohormonal Imaging to Heart Failure, Transplantation, and Diabetes

Author: Mark I. Travin

Published in: Current Cardiovascular Imaging Reports | Issue 4/2015

Login to get access

Abstract

The neurohormonal system adapts to body demands, but in cardiac disease it can become maladaptive. A key component, the sympathetic nervous system, can be imaged with radiotracers such as iodine-123-meta-iodobenzylguanidine (123I-mIBG), a norepinephrine analogue. Parameters assessed are the heart-to-mediastinal ratio (HMR), tracer washout, and regional single photon emission computed tomography (SPECT) defects. Much focus has been on heart failure that has a large neurohormonal pathophysiologic component. 123I-mIBG imaging has powerful risk stratification ability for this high morbidity/mortality condition. A lower HMR increases the likelihood of clinical worsening, ventricular arrhythmias, and cardiac death. 123I-mIBG imaging could potentially guide the use of biventricular pacemakers and ventricular assist devices. Much focus has been on better identifying patients likely to benefit from an implantable cardiac defibrillator. For patients with heart transplant, imaging with 123I-mIBG or the positron emission tomographic (PET) tracer, 11C-hydroxyephedrine (HED), can monitor recovery. In diabetes mellitus, imaging can recognize risk from cardiac autonomic dysfunction prior to clinical manifestations.
Literature
1.
Bell DR. Control mechanisms in circulatory function. In: Rhoades RA, Bell DR, editors. Medical physiology: principles of clinical medicine. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2013. p. 317–20.
2.
3.
4.
Zipes DP. Autonomic modulation of cardiac arrhythmias. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: from cell to bedside. 2nd ed. Philadelphia: W.B. Saunders Company; 1995. p. 441–2.
5.
Carrió I. Cardiac neurotransmission imaging. J Nucl Med. 2001;42(7):1062–76.PubMed
6.
Travin MI. Cardiac neuronal imaging at the edge of clinical application. Cardiol Clin. 2009;27:311–27.CrossRefPubMed
7.
8.
Sisson JC, Wieland DM. Radiolabeled meta-iodobenzylguanidine pharmacology: pharmacology and clinical studies. Am J Physiol Imaging. 1986;1:96–103.PubMed
9.
Wieland DM, Mangner TJ, Inbasekaran MN, et al. Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines. J Med Chem. 1984;27:149–55.CrossRefPubMed
10.
Kline RC, Swanson DP, Wieland DM, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981;22:129–32.PubMed
11.
Raffel DM, Wieland DM. Development of mIBG as a cardiac innervation imaging agent. J Am Coll Cardiol Img. 2010;3:111–6.CrossRef
12.
Flotats A, Carrió I, Agostini D, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37:1802–12.CrossRefPubMed
13.
Jacobson AF, Lombard J, Banerjee G, Camici PG. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. J Nucl Cardiol. 2009;16:113–21.CrossRefPubMed
14.
15.
Holly TA, Abbott BG, Al-Mallah M, et al. Single photon-emission computed tomography. J Nucl Cardiol. 2010;17:941–73.CrossRefPubMed
16.
Verberne HJ, Feenstra C, de Jong WM, et al. Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging. 2005;32:1100–7.CrossRefPubMed
17.
Agostini D, Belin A, Amar MH, et al. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-MIBG scintigraphic study. J Nucl Med. 2000;41:845–51.PubMed
18.
Gerson MC, Craft LL, McGuire N, et al. Carvedilol improves left ventricular function in heart failure with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol. 2002;9:608–15.CrossRefPubMed
19.
Yamada T, Shimonagata T, Fukunami M, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure. J Am Coll Cardiol. 2003;41:231–8.CrossRefPubMed
20.
Hattori N, Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart. What have we learned clinically? Eur J Nucl Med. 2000;27:1–6.CrossRefPubMed
21.
Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212–21.CrossRefPubMed
22.
Chen GP, Tabibiazar R, Branch KR, et al. Cardiac receptor physiology and imaging: an update. J Nucl Cardiol. 2005;12:714–30.CrossRefPubMed
23.
Morozumi T, Kusuoka H, Fukuchi K, et al. Myocardial iodine-123-metaiodobenzylguanidine images and autonomic nerve activity in normal subjects. J Nucl Med. 1997;38:49–52.PubMed
24.
Ogita H, Shimonagata T, Fukunami M, et al. Prognostic significance of cardiac 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart. 2001;86:656–60.CrossRefPubMedCentralPubMed
25.
Veltman CE, Boogers MJ, Meinardi JE, et al. Reproducibility of planar 123I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure. Eur J Nucl Med Mol Imaging. 2012;39:1599–608.CrossRefPubMedCentralPubMed
26.
Minardo JD, Tuli MM, Mock BH, et al. Scintigraphic and electrophysiologic evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation. 1988;78:1008–19.CrossRefPubMed
27.
Bax JJ, Kraft O, Buxton AE, et al. 123I-mIBG Scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: a prospective multicenter pilot study. Circ Cardiovasc Imaging. 2008;1:131–40.CrossRefPubMed
28.
Boogers MJ, Borleffs CJ, Henneman MM, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol. 2010;55:2769–77.CrossRefPubMed
29.
Marshall A, Cheetham A, George RS, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts ventricular arrhythmia in heart failure patients receiving an implantable cardioverter-defibrillator for primary prevention. Heart. 2012;98:1359–65.CrossRefPubMed
30.
Verberne HJ, Henzlova MJ, Jain D, et al. Regional myocardial mismatch between 123I-MIBG and 99mTc-tetrofosmin SPECT for the prediction of arrhythmic events in ischemic heart failure patients. J Nucl Cardiol. 2014;21:799. abstract.
31.
Go AS, Mozaffarian D, Roger VL, On behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–292.CrossRefPubMed
32.
33.
Schofer J, Spielmann R, Schuchert A, et al. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1988;12:1252–8.CrossRefPubMed
34.
Merlet P, Valette H, Dubois-Randé J, et al. Prognostic value of cardiac metaiodobenzylguanidine in patients with heart failure. J Nucl Med. 1992;33:471–7.PubMed
35.
Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579–90.CrossRefPubMed
36.
Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147–59.CrossRefPubMed
37.
Agostini D, Verberne HJ, Burchert W, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2008;35:535–46.CrossRefPubMed
38.
Nakata T, Nakajima K, Yamashina S, et al. A pooled analysis of multicenter cohort studies of I-123-mIBG cardiac sympathetic innervation imaging for assessment of long-term prognosis in chronic heart failure. J Am Coll Cardiol Img. 2013;6:772–84.CrossRef
39.
Shaw LJ, Min JK, Hachamovitch R, et al. Cardiovascular imaging research at the crossroads. J Am Coll Cardiol Imaging. 2010;3:316–24.CrossRef
40.
Treglia G, Stefanelli I, Giordano BA. Clinical usefulness of myocardial innervation imaging using iodine-123-meta-iodobenzylguanidine scintigraphy in evaluating the effectiveness of pharmacological treatments in patients with heart failure: an overview. Eur Rev Med Pharmacol Sci. 2013;17:56–8.PubMed
41.
Toyama T, Aihara Y, Iwasaki T, et al. Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after β-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med. 1999;40:217–23.PubMed
42.
Takeishi Y, Atsumi H, Fujiwara S, et al. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med. 1997;38:1085–9.PubMed
43.
Kasama S, Toyama T, Kumakura H, et al. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med. 2003;44:884–90.PubMed
44.
Kasama S, Toyama T, Kumakura H, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med. 2002;43:1279–85.PubMed
45.
Choi JY, Lee KH, Hong KP, et al. Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. J Nucl Cardiol. 2001;8:4–9.CrossRefPubMed
46.
Udelson JE, Shafer CD, Carrió I. Radionuclide imaging in heart failure: assessing etiology and outcomes and implications for management. J Nucl Cardiol. 2002;9:S40–52.CrossRef
47.
Jessup M, Abraham WT, Casey DE, Writing on behalf of the 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult Writing Committee, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;53:1343–82.CrossRef
48.
Kremers MS, Hammill SC, Berul CI, et al. The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm. 2013;10:e59–65.CrossRefPubMed
49.
Myerburg RJ. Implantable cardioverter-defibrillators after myocardial infarction. N Engl J Med. 2008;359:2245–53.CrossRefPubMed
50.
51.
Lee DS, Krahn AD, Healey JS, et al. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol. 2010;55:774–82.CrossRefPubMed
52.
Vollmann D, Lüthje L, Vonhof S, Unterberg C. Inappropriate therapy and fatal proarrhythmia by an implantable cardioverter-defibrillator. Heart Rhythm. 2005;2:307–9.CrossRefPubMed
53.
McGhie AI, Corbett JR, Akers MS, et al. Regional cardiac adrenergic function using I-123 MIBG SPECT imaging after acute myocardial infarction. Am J Cardiol. 1991;67:236–42.CrossRefPubMed
54.
Stanton MS, Tuli MM, Radtke NL, et al. Regional sympathetic denervation after MI in humans detected noninvasively using I-123-MIBG. J Am Coll Cardiol. 1989;14:1519–26.CrossRefPubMed
55.
Gerson MC, Abdallah M, Muth JN, Costea AI. Will imaging assist in the selection of patients with heart failure for an ICD? J Am Coll Cardiol Imaging. 2010;3:101–10.CrossRef
56.
Arora R, Ferrick KJ, Nakata T, et al. I-123 MIBG imaging and heart rate variability analysis to predict the needs for an implantable cardioverter defibrillator. J Nucl Cardiol. 2003;10:121–31.CrossRefPubMed
57.
Nagahara D, Nakata T, Hashimoto A, et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med. 2008;49:225–33.CrossRefPubMed
58.
Kasama S, Toyama T, Sumino H, et al. Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med. 2008;49:907–14.CrossRefPubMed
59.
Tamaki S, Yamada T, Okuyama Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol. 2009;53:426–35.CrossRefPubMed
60.
Passman R, Goldberger JJ. Predicting the future: risk stratification for sudden cardiac death in patients with left ventricular dysfunction. Circulation. 2012;125:3031–7.CrossRefPubMed
61.
Buxton AE. Not everyone with an ejection fraction ≤30% should receive an ICD. Circulation. 2005;111:2537–49.CrossRefPubMed
62.•
Shah AM, Bourgoun M, Narula J, et al. Influence of ejection fraction on the prognostic value of sympathetic innervation imaging with iodine-123 MIBG in heart failure. J Am Coll Cardiol Img. 2012;5:1139–46. A subanalysis of ADMIRE-HF data showing that 123I-mIBG imaging also has risk stratification utility in patients with LVEFs ≥35%. CrossRef
63.
Inoue H, Zipes DP. Results of sympathetic denervation in the canine heart: supersensitivity that may be arrhythmogenic. Circulation. 1987;75:877–87.CrossRefPubMed
64.
65.
Simões MV, Barthel P, Matsunari I, et al. Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J. 2004;25:551–7.CrossRefPubMed
66.
Luisi Jr AJ, Suzuki G, Dekemp R, et al. Regional 11C-hydroxyephedrine retention in hibernating myocardium: chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med. 2005;46:1368–74.PubMed
67.••
Fallavollita JA, Heavey BM, Luisi Jr AJ, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol. 2014;63:141–9. A study of patients with hibernating myocardium showing that adrenergic imaging, here with the PET tracer 11C-HED, is effective at identifying patient at increased risk of life threatening arrhythmic events. CrossRefPubMedCentralPubMed
68.
Sinusas AJ, Lazewatsky J, Brunetti J, et al. Biodistribution and radiation dosimetry of LMI1195: first-in-human study of a novel 18F-labeled tracer for imaging myocardial innervation. J Nucl Med. 2014;55:1–7.CrossRef
69.
Matsui T, Tsutamoto T, Maeda K, et al. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments—comparison with neurohumoral factors. Circ J. 2002;66:537–43.CrossRefPubMed
70.
Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60:1297–313.CrossRefPubMed
71.
Scholtens AM, Braat AJ, Tuinenburg A, et al. Cardiac sympathetic innervation and cardiac resynchronization therapy. Heart Fail Rev 2013 Jun 9.
72.
D’Orio Nishioka SA, Filho MM, Soares Brandāo SC, et al. Cardiac sympathetic activity pre and post resynchronization therapy evaluated by 123I-MIBG myocardial scintigraphy. J Nucl Cardiol. 2007;14:852–9.CrossRef
73.
Tanaka H, Tatsumi K, Fujiwara S, et al. Effect of left ventricular dyssynchrony on cardiac sympathetic activity in heart failure patients with wide QRS duration. Circ J. 2012;76:382–9.CrossRefPubMed
74.
Erol-Yilmaz A, Verberne HJ, Schrama TA, et al. Cardiac resynchronization induces favorable neurohumoral changes. Pacing Clin Electrophysiol. 2005;28:304–10.CrossRefPubMed
75.
Higuchi K, Toyama T, Tada H, et al. Usefulness of biventricular pacing to improve cardiac symptoms, exercise capacity and sympathetic nerve activity in patients with moderate to severe chronic heart failure. Circ J. 2006;70:703–9.CrossRefPubMed
76.
Gould PA, Kong G, Kalff V, et al. Improvement in cardiac adrenergic function post biventricular pacing for heart failure. Europace. 2007;9:751–6.CrossRefPubMed
77.
Miyagawa S, Sawa Y, Fukushima N, et al. Analysis of sympathetic nerve activity in end-stage cardiomyopathy patients receiving left ventricular support. J Heart Lung Transplant. 2001;20:1181–7.CrossRefPubMed
78.
Drakos SG, Athanasoulis T, Malliaras KG, et al. Myocardial sympathetic innervation and long-term left ventricular mechanical unloading. J Am Coll Cardiol Img. 2010;3:64–70.CrossRef
79.•
George RS, Birks EJ, Cheetham A, et al. The effect of long-term left ventricular assist device support on myocardial sympathetic activity in patients with non-ischaemic dilated cardiomyopathy. Eur J Heart Fail. 2013;15:1035–43. A small pilot study showing that 123I-mIBG imaging may help identify patents who are candidates for LVADs explantation. CrossRefPubMed
80.
Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation. 2010;1222:173–83.CrossRef
81.
O’Neill J, Young J, Pothier C, Lauer M. Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta blockers. Circulation. 2005;111:2313–8.CrossRefPubMed
82.
Aaronson K, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95:2660–7.CrossRefPubMed
83.
Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113:1424–33.CrossRefPubMed
84.
Cohen-Solal A, Esanu Y, Logeart D, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol. 1999;33:759–660.CrossRefPubMed
85.
Gerson MC, McGuire N, Wagoner LE. Sympathetic nervous system function as measured by I-123 metaiodobenzylguanidine predicts transplant-free survival in heart failure patients with idiopathic dilated cardiomyopathy. J Card Fail. 2003;9:384–91.CrossRefPubMed
86.
Ketchum ES, Jacobson AF, Caldwell JH, et al. Selective improvement in Seattle Heart Failure Model risk stratification using iodine-123 meta-iodobenzylguanidine imaging. J Nucl Cardiol. 2012;19:1007–16.CrossRefPubMed
87.••
Verschure DO, Veltman CE, Manrique A, et al. For what endpoint does myocardial 123I-MIBG scintigraphy have the greatest prognostic value in patients with chronic heart failure? Results of a pooled individual patient data meta-analysis. Eur Heart J Cardiovasc Imaging. 2014 Mar 30. Pooled prospectively acquired 123 I-mIBG data of 636 patients from 6 European and US sites showing the utility of imaging for predicting a variety of adverse cardiac events, but that planar HMR may be less useful for predicting arrhythmic events.
88.
Flotats A, Carrió I. Value of radionuclide studies in cardiac transplantation. Ann Nucl Med. 2006;20:13–21.CrossRefPubMed
89.
Di Carli MF, Tobes MC, Mangner T, et al. Effects of cardiac sympathetic innervation on coronary blood flow. N Engl J Med. 1997;336:1208–15.CrossRefPubMed
90.
Estorch M, Campreciós M, Flotats A, et al. Sympathetic reinnervation of cardiac allografts evaluated by 123I-MIBG imaging. J Nucl Med. 1999;40:911–6.PubMed
91.
Bengel FM, Ueberfuhr P, Schiepel N, et al. Effect of sympathetic reinnervation on cardiac performance after heart transplantation. N Engl J Med. 2001;345:731–8.CrossRefPubMed
92.•
Gerson MC, Caldwell JH, Ananthasubramaniam K, et al. Influence of diabetes mellitus on prognostic utility of imaging of myocardial sympathetic innervation in heart failure patients. Circ Cardiovasc Imaging. 2011;4:87–93. A study of about 1000 patients showing that in diabetic heart failure patients an HMR <1.6 is associated with an almost threefold increase in heart failure progression. Thus, therapies that prevent or ameliorate identified cardiac denervation in these patients may be a beneficial addition to therapies focused primarily on the diabetes. CrossRefPubMed
93.
Lee K-H, Jang H-J, Lee EJ, et al. Prognostic value of cardiac autonomic neuropathy independent and incremental to perfusion defects in patients with diabetes and suspected coronary artery disease. Am J Cardiol. 2003;92:1458–61.CrossRefPubMed
94.
Gerritsen J, Dekker JM, TenVoorde BJ, et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care. 2001;24:1793–8.CrossRefPubMed
95.
Langer A, Freeman MR, Josse RG, et al. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol. 1995;25:610–8.CrossRefPubMed
96.
Hattori N, Tamaki N, Hayashi T, et al. Regional abnormality of iodine-123-MIBG in diabetic hearts. J Nucl Med. 1996;37:1985–90.PubMed
97.
Stevens MJ, Raffel DM, Allman KC, et al. Cardiac sympathetic dysinnervation in diabetes. Implications for enhanced cardiovascular risk. Circulation. 1998;98:961–8.CrossRefPubMed
98.
Sacre JW, Franjic B, Jellis CL, et al. Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes. JACC Cardiovasc Imaging. 2010;3:1207–15.CrossRefPubMed
99.
Nagamachi S, Fujita S, Nishii R, et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol. 2006;13:34–42.CrossRefPubMed
100.
Paolillo S, Rengo G, Pagano G, et al. Impact of diabetes on cardiac sympathetic innervation in patients with heart failure: a 123I meta-iodobenzylguanidine (123I MIBG) scintigraphic study. Diabetes Care. 2013;36:2395–401.CrossRefPubMedCentralPubMed
Metadata
Title
Application of Cardiac Neurohormonal Imaging to Heart Failure, Transplantation, and Diabetes
Author
Mark I. Travin
Publication date
01-04-2015
Publisher
Springer US
Published in
Current Cardiovascular Imaging Reports / Issue 4/2015
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-015-9323-3

Other articles of this Issue 4/2015

Current Cardiovascular Imaging Reports 4/2015 Go to the issue

Intravascular Imaging (I-K Jang, Section Editor)

Dye-Staining Angioscopy for Coronary Artery Disease

Specific Populations and Emerging Markets (V Dilsizian and T Schindler, Section Editors)

Relatively High Prevalence of Takotsubo Cardiomyopathy (Stress-Induced Cardiomyopathy) in the Japanese Population—Contribution of Cardiac Imaging in the Identification of Takotsubo Cardiomyopathy and its Differentiation from Acute Coronary Syndrome

Specific Populations and Emerging Markets (V Dilsizian and T Schindler, Section Editors)

State of Overall Cardiovascular Risk and Imaging Strategies in India

Specific Populations and Emerging Markets (V Dilsizian and T Schindler, Section Editor)

Cardiac Imaging in Latin America: Chagas Heart Disease

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits